LIVE Webinar
Tuesday, July 10th, 2018
1:00 – 2:00 pm EST
Acute myeloid leukemia (AML) is a disease of older adults, with a median age of presentation of 67 years; only 5-10% of patients are alive at 5 years. Traditionally older patients have not received intensive induction chemotherapy to avoid toxicities, yet current research shows fit patients treated with intensive chemotherapy have better outcomes than patients with no treatment.
The goal of this program is to close existing cancer clinician competency gaps regarding new data on investigational agents for AML along with evolving evidence-based guidelines and current understanding of treatment outcomes among older patients with AML. Hematology care teams will receive updates on current treatment treatments, the new data on investigational agents for AML, and how to make risk-based decisions among older patients with AML.
Learning Objectives
At the conclusion of this educational initiative, participants should be able to:
- Recall new data on investigational agents for AML and evolving evidence based guidelines and current understanding of treatment outcomes among older patients with AML
- Recognize new data regarding the screening and management of older patients with AML
- Employ an electronic screening tool in clinic to evaluate frailty status among older patients newly diagnosed AML or those needing a new line of therapy
Faculty
Thomas W. LeBlanc, MD
Associate Professor of Medicine Duke Cancer Institute
Ashley Leak Bryant, PhD, RN-BC, OCN
University North Carolina Lineberger Comprehensive Cancer Center
Agenda (All times in EST)
| 1:00 – 1:05 pm | Program Overview | |
| 1:05 – 1:30 pm | AML Treatment Update | Thomas LeBlanc, MD Associate Professor of Medicine Duke Cancer Institute |
| 1:30 – 1:55 pm | Geriatric Assessment for Older Patients with AML | Ashley Leak Bryant, PhD, RN, OCN University North Carolina Lineberger |
| 1:55 – 2:00 pm | Q&A | Expert Panel & Audience |
Who Should Attend?
This activity is intended for hematologists, hematology Nurse Practitioners (NPs) and Physician Assistants (PAs) and oncology nurses engaged in the care of patients with acute myelogenous leukemia (AML).
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Carevive Systems, Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
Faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Faculty Disclosures
Thomas LeBlanc, MD Royalty Fees, UpToDate, Inc., Consulting Fees, Amgen, Heron, Helsinn, Otsuka; Speaker Fees, Celgene, Contracted Research, AstraZeneca, Seattle Genetics.
Ashley Leak Bryant PhD, RN-BC, OCN has no real or apparent conflicts of interest to report.
Planners and Managers
The PIM planners and managers have nothing to disclose. The Carevive planners and managers have nothing to disclose.
Fee Information
There is no fee for this educational activity.
This activity is supported by independent educational grants from AbbVie, Astellas, Celgene, and Jazz Pharma.
Jointly provided by Postgraduate Institute for Medicine and Carevive Systems, Inc. 
